EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

KRAS-mediated CCDC6 degradation drives xCT upregulation and ferroptosis evasion

Daniela Criscuolo, Rosaria Catalano, Carmela Baviello, Claudia Fioravanti, Elena Vigliar, Francesco Morra, Maria Marotta, Junsei Mimura, Antonino Iaccarino, Francesco Pepe, Dorina Belotti, Giancarlo Troncone und 3 weitere

Apoptosis · 2026-08 · 31 (8)

DOI: 10.1007/s10495-026-02400-4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Apoptosis, online erschienen am 14.07.2026. Verfasst von Daniela Criscuolo und 14 weiteren Autor:innen. Beteiligte Einrichtung: CNR-Institute of Endotypes in Oncology, Metabolism and Immunology "G Salvatore"-IEOMI, Via Pansini, 5, Naples, Italy. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins p21(ras), Ferroptosis, Amino Acid Transport System y+. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Consiglio Nazionale Delle Ricerche.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Oncogenic KRAS mutations drive tumorigenesis by promoting pro-survival signaling and metabolic reprogramming, including the maintenance of redox balance to evade oxidative stress. A key mechanism involves the upregulation of the xCT cystine/glutamate antiporter, which sustains glutathione (GSH) synthesis and protects cells from oxidative damage and ferroptosis. While it is known that the ETS1-ATF4 complex mediates transcriptional upregulation of xCT, the upstream regulators linking KRAS signaling to this axis remain to be fully defined. Here, we demonstrate that oncogenic KRAS signaling induces the GSK3β-mediated proteasomal degradation of the tumor suppressor CCDC6. We show that CCDC6 acts as a negative regulator of the xCT-promoting transcription factor ATF4 by directly interacting with it and preventing its recruitment to the xCT promoter. Consequently, KRAS-driven CCDC6 degradation disinhibits ATF4, leading to increased xCT expression, elevated intracellular GSH, and enhanced resistance to ferroptosis. Crucially, pharmacological inhibition of CCDC6 turnover using proteasome, GSK3β, or specific KRAS mutant inhibitors (Sotorasib, Adagrasib, HRS4642) restored CCDC6 protein levels and robustly sensitized KRAS-mutated cells to ferroptosis-inducing agents like Sulfasalazine. Furthermore, validation in preclinical models and human colorectal cancer samples revealed that CCDC6 protein levels are predominantly downregulated in KRAS-mutant cases. This work uncovers a novel KRAS/CCDC6/xCT signaling axis that mediates ferroptosis resistance in KRAS-mutated cancers. Moreover, it identifies CCDC6 turnover as a critical vulnerability and a promising therapeutic target to enhance the efficacy of ferroptosis-inducing agents.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proto-Oncogene Proteins p21(ras)FerroptosisAmino Acid Transport System y+HumansActivating Transcription Factor 4Up-RegulationSignal TransductionGlycogen Synthase Kinase 3 betaGlutathioneCell Line, TumorGene Expression Regulation, NeoplasticProteolysisAnimalsProteasome Endopeptidase ComplexMutation

Stichwörter der Autor:innen

ATF4Oxidative stressPrecision medicineRas-mutated tumorsRepurposing drugs

Substanzen

Proto-Oncogene Proteins p21(ras)KRAS protein, humanSLC7A11 protein, humanAmino Acid Transport System y+Activating Transcription Factor 4ATF4 protein, humanGlycogen Synthase Kinase 3 betaGlutathioneProteasome Endopeptidase Complex

Autor:innen und Institutionen

  • CNR-Institute of Endotypes in Oncology, Metabolism and Immunology "G Salvatore"-IEOMI, Via Pansini, 5, Naples, Italy.
  • Department of Medicine and Health Sciences, University of Molise, Campobasso, Italy.
  • Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri, IRCCS, Bergamo, Italy.
  • Department of Public Health, "Federico II" University, Naples, Italy.
  • Department of Stress Response Science, Biomedical Research Center, Hirosaki Graduate School of Medicine, Zaifucho, Hirosaki, Japan.
  • Department of Neurosciences, Reproductive and Odontostomatological Sciences, "Federico II" University, Naples, Italy.

Förderung

  • Consiglio Nazionale Delle Ricerche

Zitieren

APA

Criscuolo, D., Catalano, R., Baviello, C., Fioravanti, C., Vigliar, E., Morra, F., Marotta, M., Mimura, J., Iaccarino, A., Pepe, F., Belotti, D., Troncone, G., Merolla, F., Melillo, R. M., & Celetti, A. (2026). KRAS-mediated CCDC6 degradation drives xCT upregulation and ferroptosis evasion. Apoptosis, 31(8). https://doi.org/10.1007/s10495-026-02400-4

Vancouver

Criscuolo D, Catalano R, Baviello C, Fioravanti C, Vigliar E, Morra F, et al. KRAS-mediated CCDC6 degradation drives xCT upregulation and ferroptosis evasion. Apoptosis. 2026;31(8). doi:10.1007/s10495-026-02400-4

BibTeX
@article{Criscuolo2026,
  author = {Criscuolo, Daniela and Catalano, Rosaria and Baviello, Carmela and Fioravanti, Claudia and Vigliar, Elena and Morra, Francesco and Marotta, Maria and Mimura, Junsei and Iaccarino, Antonino and Pepe, Francesco and Belotti, Dorina and Troncone, Giancarlo and Merolla, Francesco and Melillo, Rosa Marina and Celetti, Angela},
  title = {KRAS-mediated CCDC6 degradation drives xCT upregulation and ferroptosis evasion},
  journal = {Apoptosis},
  year = {2026},
  volume = {31},
  number = {8},
  doi = {10.1007/s10495-026-02400-4}
}
Kostenlos starten →